Plain language summary
======================

The expression of HIPK3 mRNA and protein level was significantly downregulated in human non-small-cell lung cancer (NSCLC). Low expression of HIPK3 was significantly associated with pathology grade, TNM stage, lymph node metastasis, Ki-67 expression, and 5-year survival rate in NSCLC patients. HIPK3 silencing promoted invasion and metastasis in NSCLC. HIPK3 could be potentially used as a valuable biomarker for predicting the prognosis of NSCLC patients.

Introduction
============

According to the statistical analysis released by the American Cancer Society, in 2018, there were \~234,030 newly diagnosed patients with lung cancer, accounting for 13.5% of all newly diagnosed malignancies. In addition, \~154,050 people died from lung cancer each year, accounting for 25.3% of all cancer-related deaths.[@b1-ott-11-7459] China has not escaped this worldwide trend, and the data being gathered in the country on the cause of death have ranked lung cancer as the first among all malignant tumor deaths for 7 consecutive years. For example, in Beijing, the number of deaths due to lung cancer nearly tripled between 1974 and 2003.

In general, lung cancer cells are classified into two types -- non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC).[@b2-ott-11-7459] NSCLC accounts for 80%--85% of all lung cancers.[@b3-ott-11-7459] The treatment for lung cancer is mainly surgery in combination with chemotherapy, radiotherapy, immuno-therapy, and so on. Despite the advances in cancer treatments, the 5-year survival rate for lung cancer remains \<18%[@b4-ott-11-7459],[@b5-ott-11-7459] mainly due to the failure of early detection and diagnosis of the disease. In \~85% of patients, the primary lesion will metastasize and invade lymph nodes or other organs at the late stage; at this stage, the treatment is not effective and the prognosis is poor. Therefore, early diagnosis and a comprehensive treatment to prevent and control NSCLC metastasis are critical to reduce mortality.

FAS/HIPK, a member of the *HIPK* family of genes, was discovered in 1998 by Kim et al[@b6-ott-11-7459] through the double hybridization of yeast and by obtaining the main cDNA clone of this family member. The family comprises *HIPK1*, *HIPK2*, *HIPK3*, and *HIPK4*, of which, we focus on *HIPK3* in this study.

There have been few studies on *HIPK3*, especially on its association with lung cancer. In this study, we confirmed a lower expression of *HIPK3* in NSCLC tissues than in normal lung tissues and demonstrated that *HIPK3* played a role in the proliferation, migration, and invasion of these cancer cells. Our findings suggested that *HIPK3* had potential clinical applications as a prognostic predictor or therapeutic target in NSCLC.

Materials and methods
=====================

Patients and tissue samples
---------------------------

A total of 206 samples were obtained from patients who had undergone lung resection without immunotherapy or radiation therapy at the Thoracic Surgery Department of the Affiliated Hospital of Nantong University (Nantong, China) between May 2008 and July 2010. Quantitative real-time qRT-PCR was used to investigate 30 patients who underwent curative resection between January 2015 and August 2016 at the same hospital. Follow-up of all patients was completed by May 2017. The tissues that were previously pathologically determined to be NSCLC and matching non-cancerous tissues were obtained from each patient. The procedure was approved by the research ethics committee of the Affiliated Hospital of Nantong University (Nantong, China), and the written informed consent was obtained from each patient.

qRT-PCR analysis
----------------

For qRT-PCR analysis, total RNA was isolated from NSCLC samples using TRIzol (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer's protocol. Reverse transcription and PCR were performed using a High Capacity cDNA Reverse Transcription Kit and QuantiTect SYBR Green PCR Kit (Thermo Fisher Scientific). The primer sequences for the genes were defined as follows: *HIPK3*: forward 5′-ACATTGGAAGAGCATGAGG CAGAGA-3′; reverse 5′-CTGCTGAAAAGCATCAC CACAACCA-3′*GAPDH*: forward 5′-GCAGGGGGGAGCCAAAA GGGT-3′; reverse 5′-TGGGTGGCAGTGATGGCA TGG-3′.

Immunohistochemical (IHC) evaluation
------------------------------------

For statistical analyses, the number of cells showing SYBR green staining on the nuclei and cytoplasm in 10 representative microscopic fields were counted, and the percentage of positive cells was calculated. A semiquantitative assessment of the IHC reactions for *HIPK3* was used to score staining results as follows: 0 (negative, ≤5% of cells), 1+ (low, 6%--25%), 2+ (intermediate, 26%--50%), and 3+ (high, ≥51%). The count was recorded as the percentage of positive cells. In one-half of the samples, staining was repeated three times to avoid potential technical errors. The evaluation procedures were independently performed by three experienced pathologists using a multi-head microscope (Precise Instrument Co., Ltd., Beijing, China) to reach a consensus.

In addition to the aforementioned method, another quantitative evaluation method was used. HIPK3 sections were scanned by NanoZoomer slide scanners (NanoZoomer-XR C12000; Hamamatsu, Japan) and observed with NDP. view software (NDP.view2 U12388-01; Hamamatsu). The tumor area was determined as a 20× field (545×577 µm^2^) viewed by NDP.view in the center. The number of HIPK3 cells was counted in four hotspots (20×) using a computer-automated method (Imagepro plus 6.0; Media Cybernetics Inc., Bethesda, MD, USA), and then mean densities were calculated. The cutoff value of the HIPK3 cell counts was determined by the 5-year survival-specific receiver operating characteristic curve analysis according to the Youden's index. Then, a low HIPK3 cell count was not more than the cutoff value and a high HIPK3 cell count was greater than the cutoff value.

Cell culture and transfection
-----------------------------

A549 and HCC827 cells were purchased from the American Type Culture Collection (Manassas, VA, USA) and cultured in Dulbecco's Modified Eagle's Medium supplemented with 10% FBS. Cells were transfected with *HIPK3* siRNA (Genepharma, Suzhou, China) and their corresponding negative control (siRNA ctrl) at a final concentration of 50 nmol/L using Lipofectamine 2000 Transfection Reagent (Thermo Fisher Scientific) according to the manufacturer's instructions.

Cell invasion and cell migration
--------------------------------

Transwell membranes (8 µm pore size) on 24-well plates were coated with Matrigel (BD Biosciences, San Jose, CA, USA) and used for cell invasion assays. Equal numbers (1×10^5^) of nontransfected cells and cells transfected with siRNA-targeting *HIPK3* (siR-*HIPK3*) or *HIPK3* vector were plated in separate wells. The cells were cultured overnight in a serum-free medium before being trypsinized and resuspended at a density of 2×10^5^ cells/mL in a medium containing 2% FBS. The cells were then added to the upper chamber of the incubator with medium containing 20% FBS as the chemoattractant in the lower chamber. Medium containing 2% FBS was added to the lower chamber and used as the control. Matrigel and the cells remaining in the upper chamber were removed using cotton swabs following incubation for 24 hours. The cells on the lower surface of the membrane were fixed with formaldehyde solution and stained with staining solution. The cells in at least five random microscopic fields (×200) were counted and photographed. For the migration assay, the transfected cells were plated and incubated until the formation of 80%--90% confluent monolayer. AP-20 micropipette tips were then used to mimic a scratch wound. The ratio of migratory capacity was determined by measuring the width of the scratch at 0 and 24 hours using bright-field microscopy.

Tumor xenograft model in nude mice
----------------------------------

The nude mouse xenograft model was developed, which was xenografted with a human lung cancer cell line, NSCLC A549 cell. This mice model was obtained from Shanghai Animal Experimental Center. Mice were randomly divided into four groups, with four mice in each group, namely the pcDNA3.1 control group (group A), normal saline control group (group B), HIPK3-shRNA group (group C), and HIPK3 overexpression group (group D). All supplied mice were female and weighed 19--20 g. All treatments were administered for 4 weeks.

Western blot analysis
---------------------

For Western blotting, 50 µg protein was separated by SDS-PAGE and transferred onto polyvinylidene difluoride (PVDF) membranes. The membranes were blocked with 5% nonfat milk for 1 hour and incubated overnight at 4°C with their corresponding primary antibodies (1:1,000 dilution in 5% nonfat milk), followed by incubation with secondary antibodies conjugated with horseradish peroxidase (HRP; 1:8,000 dilution in 5% nonfat milk) for 2 hours at room temperature. The membranes were then detected using an electrogenerated chemiluminescence kit (Thermo Fisher Scientific).

Statistical analyses
--------------------

All computations were performed using SPSS, Version 24.0 (IBM Corporation, Armonk, NY, USA). All values were expressed as the mean±standard error. *HIPK3* expression and clinicopathological features were analyzed using Pearson's chi-squared test. Univariate and multivariate analyses were performed using the Cox regression model to test independent prognostic factors, and 95% CI was recorded for each marker. Kaplan--Meier analysis and the log-rank test were used to analyze the survival rate. A *P*-value \<0.05 was considered statistically significant.

Results
=======

Decreased *HIPK3* expression in NSCLC tissues
---------------------------------------------

The protein and mRNA levels of *HIPK3* expression were quantified using Western blotting and qRT-PCR, respectively, in NSCLC tissues and normal tissues. As illustrated in [Figure 1](#f1-ott-11-7459){ref-type="fig"}, both Western blotting and qRT-PCR showed a visible decrease in *HIPK3* expression levels in NSCLC tissues compared with that in normal tissues.

Decreased *HIPK3* expression in NSCLC tissues was associated with poor clinicopathological characteristics
----------------------------------------------------------------------------------------------------------

IHC was performed in 206 NSCLC tissue samples to investigate the HIPK3 protein expression profile. The cytoplasm and nucleus of the carcinoma cells showed positive immunostaining ([Figure 2](#f2-ott-11-7459){ref-type="fig"}). [Table 1](#t1-ott-11-7459){ref-type="table"} shows the relationship between the expression of HIPK3 and the clinicopathological characteristics of the tissue samples from 206 NSCLC patients. We identified that HIPK3 protein expression was significantly associated with pathology grade (*P*=0.004), TNM stage (*P*=0.002), lymph node metastasis (*P*=0.010), Ki-67 expression (*P*=0.015), and 5-year survival rate in NSCLC patients (*P*=0.001). However, there was no correlation between HIPK3 protein expression and other prognostic factors such as age, sex, tumor diameter, smoking status, and histological type.

Decreased HIPK3 protein expression in NSCLC predicted poor survival
-------------------------------------------------------------------

Univariate and multivariate analyses were used with the Cox proportional hazards model to identify related prognostic factors for overall survival. The univariate analysis revealed that the following variables were significantly associated with a poor prognosis: *HIPK3* expression (*P*=0.001), Ki-67 expression (*P*=0.027), tumor size (*P*\<0.001), TNM stage (*P*\<0.001), and age (*P*=0.029). To verify the accuracy of the results, multivariate analysis was performed using the significant (*P*\<0.05) variables from the univariate analysis. The multivariate analysis revealed that the *HIPK3* (*P*\<0.001), tumor size (*P*\<0.001), TNM stage (*P*\<0.001), Ki-67 expression (*P*=0.027), and age (*P*=0.006) had independent prognostic value on the overall survival of NSCLC patients ([Table 2](#t2-ott-11-7459){ref-type="table"}). Kaplan--Meier survival curves revealed that a poorer prognosis was found in NSCLC patients with lower *HIPK3* expression levels ([Figure 3](#f3-ott-11-7459){ref-type="fig"}).

HIPK3 participated in multiple biological processes in NSCLC cells
------------------------------------------------------------------

To further verify the expression of *HIPK3* in NSCLC cells in vitro, *siR-HIPK3* for knocking down *HIPK3* mRNA was synthesized. Western blot analysis showed that *siR-HIPK3* reduced *HIPK3* protein levels in A549 as shown in [Figure 4A and B](#f4-ott-11-7459){ref-type="fig"}. As indicated by the results, *siR-HIPK3* promoted the migratory ability and invasive capability of the NSCLC cell line. *siR-HIPK3* further confirmed the result by enhancing the migratory ability and the invasive capability of both cell lines ([Figure 4C and D](#f4-ott-11-7459){ref-type="fig"}). To further verify the results, we repeated the experiments in another lung cancer cell line, HCC827. The aforementioned results were confirmed again in HCC827 ([Figure 5](#f5-ott-11-7459){ref-type="fig"}). Taken together, the results showed that *HIPK3* was negatively expressed in the progression and metastasis of NSCLC.

HIPK3 inhibited the proliferation of NSCLC cells in vivo
--------------------------------------------------------

We further studied the effect of HIPK3 on tumor volume in vivo, and the results showed that the overexpression of HIPK3 inhibited tumor growth and the overexpression of HIPK3-shRNA promoted tumor growth ([Figure 6A and B](#f6-ott-11-7459){ref-type="fig"}).

Discussion
==========

The function of HIPKs is to modulate cellular stress responses and regulate cell differentiation, proliferation, and apoptosis.[@b7-ott-11-7459] The *HIPK* family genes comprises *HIPK1*, *HIPK2*, and *HIPK3*, which share similar domain-frustrated structures on serine and threonine residues. Some studies have found that the expression of *HIPK*s was located mainly in the nucleus and enhanced the inhibitory activity of the natural killer (NK) protein family.[@b8-ott-11-7459] Studies by Kim et al[@b6-ott-11-7459] found that HIPKs were involved in a variety of cellular processes and played a role by mediating the phosphorylation of several important protein molecules. They represented a family of highly conserved kinases and were involved in cellular processes including regulation of cell death, proliferation, and differentiation. In addition, it has been reported that these kinases are involved in the regulation of cellular responses to DNA damage.[@b7-ott-11-7459] The HIPK family not only regulates other proteins in the nucleus, but also regulates those in the cytoplasm and cell membrane and can participate in biological processes, such as cell proliferation, differentiation, and apoptosis, by affecting the phosphorylation of corresponding proteins. The site and mode of action depend on the conditions that the protein encounters after it has been removed from the nucleus.[@b9-ott-11-7459],[@b10-ott-11-7459]

HIPK1 protein is involved in the biological processes of cell proliferation, activation, and apoptosis by regulating the phosphorylation of many proteins and activation of some signaling pathways.[@b11-ott-11-7459],[@b12-ott-11-7459] Other studies have found that HIPK1 protein plays a role in promoting apoptosis to reduce tumor progression. These findings also showed that this protein depends on partner proteins to function. For example, under certain conditions, HIPK1 phosphorylates its partner protein Daxx to redistribute within the cytoplasm by influencing localization and transcriptional repression activities in Daxx cells.[@b13-ott-11-7459],[@b14-ott-11-7459] Studies have shown that *HIPK1* plays an important role in oncogenesis and that the incidence or size of tumor formation in *HIPK1* knockout mice is significantly reduced. This suggests a phenomenon associated with DNA damage-- induced apoptosis. These data also suggest that *HIPK1* is involved, to some extent, in a reaction to repair the damaged DNA, a process that might be initiated through its interaction with p53.[@b14-ott-11-7459]

As a tumor suppressor gene, *HIPK2* is involved in the suppression of the occurrence and metastasis of several tumors. Nodale et al[@b15-ott-11-7459] found that *HIPK2* inhibited the spread of human breast cancer cells by down-regulating vimentin. Similarly, D'Orazi et al[@b16-ott-11-7459] used RNA interference (RNAi) to study the role of *HIPK2* in prostaglandin biosynthesis and found that *HIPK2* was inhibited by cytosolic phospholipase A2 (cPLA2) prostaglandin E2 (PGE2) production, thereby inhibiting the occurrence of human colon tumors. Furthermore, Guang et al[@b17-ott-11-7459] revealed that *HIPK2* could inhibit P-catenin--mediated transcription, epidermal stem cell expansion, and skin tumors.

*HIPK2* is the most studied member of the *HIPK* family of genes and is characterized by DNA damage response kinases that have both pro-apoptotic and anti-apoptotic functions to combat genotoxic and oxidative cell damage.[@b18-ott-11-7459]--[@b22-ott-11-7459] Moreover, He et al[@b23-ott-11-7459] showed that *HIPK4* not only had less sequence homology with HIPKs 1, 2, and 3, but also had a high degree of sequence homology, suggesting that this kinase is highly conserved among species.

In 1998, Kim et al.[@b6-ott-11-7459] first reported on *HIPK3* and that *HIPK3* mRNA is widely found in human and mammalian tissues. Northern blot analysis revealed that *HIPK3* is expressed asã7.5 kb tRNA, whereas in humans, *HIPK3* also contains an additional 4.4 kb transcript on chromosome seven. Young et al[@b24-ott-11-7459] labeled *HIPK3* protein with green fluorescent protein (GFP) and observed it in living cells. The GFP spots were first observed in the nucleus and later in the cytoplasm, indicating that *HIPK3* protein is first present in the nucleus as a nuclear protein kinase. The *HIPK* protein family is highly phosphorylated during apoptosis, while purified *HIPK3* can phosphorylate NK domain homology transcription factor, suggesting that its family is a group of homologous domain-transforming phosphorylation kinases. Because NK cells are one of the major cells involved in FAS-mediated apoptosis, *HIPK3* is an important factor in FAS-mediated apoptosis and is a tumor suppressor gene. In our current study, as illustrated in [Figure 1](#f1-ott-11-7459){ref-type="fig"}, both Western blotting and qRT-PCR showed a visible decrease in *HIPK3* expression levels in NSCLC tissues compared with that in the normal tissue. This result was consistent with the previous research results. Veronique et al[@b25-ott-11-7459] cloned full-length mouse and human *HIPK3* homology and found that 90% of the amino acid sequences were the same. A gene study found that an intact *HIPK3* protein molecule was consisted of an NH2-terminal kinase domain and a conserved PEST sequence, which had a COOH-terminus that could coincide with the FADD domain on FAS.

In 2004, Curtin et al[@b26-ott-11-7459] studied the role of *HIPK3* in the apoptotic prostate cancer cell line DU-145. When JNK inhibitor SP600125 was added to DU-145 and detected by Western blotting and flow cytometry, they found that as the JNK levels decreased, *HIPK3* and FAS-mediated apoptosis also decreased. After removing the JNK inhibitor, FAS-mediated apoptosis was significantly increased, *HIPK3* expression also increased, and there was a change in Caspase-3 expression levels. These results indicated that *HIPK3* was associated with FAS-mediated apoptosis. Moller[@b27-ott-11-7459] also reported *HIPK3* expression in the apoptotic human osteosarcoma cell line U20S; however, the clinical application of *HIPK3*, especially the study of *HIPK3* in clinical NSCLC specimens, has not been reported.

In our current study, IHC results demonstrated that low HIPK3 protein expression was significantly associated with pathology grade, TNM stage, lymph node metastasis, Ki-67 expression, and the 5-year survival rate of NSCLC patients. The multivariable analysis revealed that *HIPK3*, tumor size, TNM stage, Ki-67 expression, and age had independent prognostic effects on the overall survival of patients with NSCLC. Kaplan--Meier survival curves showed that NSCLC patients with higher *HIPK3* protein expression had a better prognosis. In addition, *HIPK3* knockdown using specific siRNA enhanced the migration and invasion of A549 and HCC827 cells. In vivo experiments in nude mice also demonstrated that *HIPK3* over-expression inhibited tumor growth, whereas in contrast, HIPK3-shRNA promoted tumor growth in vivo.

Conclusion
==========

Our findings confirmed that low expression of *HIPK3* in NSCLC tissues was significantly correlated with poor survival rates after curative resection. *HIPK3* could be used as a valuable biomarker for predicting the prognosis for NSCLC patients.
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![HIPK3 expression decreased in NSCLC tissues.\
**Notes:** (**A** and **B**) Levels of HIPK3 in normal lung tissues and tumor tissues were measured by Western blotting. Values are represented as mean±SD. \*\**P*\<0.01. (**C**) Quantitative real-time PCR (qRT-PCR) assays showed that HIPK3 expression was lower in NSCLC tissues than in normal lung tissues.\
**Abbreviations:** NSCLC, non-small-cell lung cancer; qRT-PCR, quantitative real-time PCR.](ott-11-7459Fig1){#f1-ott-11-7459}

![Representative images of IHC staining of HIPK3 expression in NSCLC tissue samples and benign tumors.\
**Notes:** (**A1**--**B3**) Strong staining of HIPK3 in NSCLC tissues; (**C1**--**D3**) light staining of HIPK3 in NSCLC tissues; (**E1**--**E3**) negative staining of HIPK3 in NSCLC tissues; (**F1**--**F3**) positive staining of HIPK3 in surrounding normal tissues. (**A1**--**F1**) Original magnification, ×40; (**A2**--**F2**) original magnification, ×200; (**A3**--**F3**) original magnification, ×400.\
**Abbreviations:** IHC, immunohistochemical; NSCLC, non-small-cell lung cancer.](ott-11-7459Fig2){#f2-ott-11-7459}

![Kaplan--Meier analysis revealed that the survival of NSCLC patients with high HIPK3 expression was significantly greater than the survival of NSCLC patients with low HIPK3 expression.\
**Abbreviation:** NSCLC, non-small-cell lung cancer.](ott-11-7459Fig3){#f3-ott-11-7459}

![siR-HIPK3 enhanced the migration and invasion of A549 cells.\
**Notes:** (**A** and **B**) A549 cell was transfected with siR-NC, *siR-HIPK3*, pcDNA-negative, or *HIPK3* overexpressed plasmid. At 48 hours after transfection, cell proliferation was measured by MTT assays; (**C**) number of invaded cells following *HIPK3* knockdown using specific *siR-HIPK3* vs siR-NC as shown by staining with crystal violet. Bars indicate the invasion capability compared with that of siR-NC (±SD). Magnification ×200. \*\**P*\<0.01. (**D**) Representative images of wound healing were taken at 0 hour and 24 hours after the wound was scratched. Data are presented as mean±SD. Magnification ×100. \*\**P*\<0.01.\
**Abbreviations:** NC, negative control; *siR-HIPK3*, siRNA-targeting *HIPK3*.](ott-11-7459Fig4){#f4-ott-11-7459}

![siR-HIPK3 promoted the migration and invasion of HCC827 cells.\
**Notes:** (**A** and **D**) MTT assays with siR-HIPK3 and HIPK3 overexpressed cells; (**B** and **C**) number of invaded cells following siR-HIPK3 vs siR-NC as shown by staining with crystal violet. Bars indicate the invasion capability compared with that of negative control (±SD). Magnification ×200. \**P*\<0.05, \*\**P*\<0.01. (**E** and **F**) Migration of the HCC827 cells to the wound was visualized at 0 and 24 hours with inverted Leica phase contrast microscope (×200). \*\**P*\<0.05. Each time point was derived from three independent experiments.\
**Abbreviations:** NC, negative control; siR*-HIPK3*, siRNA-targeting *HIPK3*.](ott-11-7459Fig5){#f5-ott-11-7459}

![Necropsy images of mice with orthotopically implanted of A549 cells.\
**Notes:** (**A** and **B**) Tumor volumes (mean±SD) in mice measured on the last day of the experiment. \**P*\<0.05 and ^\#^*P*\<0.05.](ott-11-7459Fig6){#f6-ott-11-7459}

###### 

Correlation of HIPK3 expression with clinicopathological characteristics of NSCLC patients

  Clinicopathological characteristics   n     Low expression, n (%)   High expression, n (%)   Chi-squared   *P*-value
  ------------------------------------- ----- ----------------------- ------------------------ ------------- --------------------------------------------------
  Total                                 206                                                                  
  Gender                                                                                       4.072         0.052
   Male                                 135   88 (65.2)               47 (34.8)                              
   Female                               71    36 (50.7)               35 (49.3)                              
  Age (years)                                                                                  0.569         0.462
   \<60                                 74    42 (56.8)               32 (43.2)                              
   ≥60                                  132   82 (62.1)               50 (37.9)                              
  Tumor diameter (cm)                                                                          2.968         0.096
   \<3                                  139   78 (56.1)               61 (43.9)                              
   ≥3                                   67    46 (68.7)               21 (31.3)                              
  Smoking status                                                                               0.651         0.573
   Never                                192   117 (60.9)              75 (39.1)                              
   Ever                                 14    7 (50.0)                7 (50.0)                               
  Pathology grade                                                                              11.279        0.004[a](#tfn1-ott-11-7459){ref-type="table-fn"}
   Well                                 35    16 (45.7)               19 (54.3)                              
   Moderate                             74    38 (51.4)               36 (48.6)                              
   Poor                                 97    70 (72.2)               27 (27.8)                              
  Histological type                                                                            1.308         0.520
   Adenocarcinoma                       131   75 (57.3)               56 (42.7)                              
   Squamous cell carcinoma              66    43 (65.2)               23 (34.8)                              
   Adenosquamous carcinoma              9     6 (66.7)                3 (33.3)                               
  TNM stage                                                                                    15.246        0.002[a](#tfn1-ott-11-7459){ref-type="table-fn"}
   I                                    45    18 (40.0)               27 (60.0)                              
   II                                   47    25 (53.2)               22 (46.8)                              
   III                                  71    53 (74.6)               18 (25.4)                              
   IV                                   43    28 (65.1)               15 (34.9)                              
  Lymph node metastasis                                                                        6.856         0.010[a](#tfn1-ott-11-7459){ref-type="table-fn"}
   Absent                               100   51 (51.0)               49 (49.0)                              
   Present                              106   73 (68.9)               33 (31.1)                              
  Ki67 expression                                                                              6.624         0.015[a](#tfn1-ott-11-7459){ref-type="table-fn"}
   Low                                  69    33 (47.8)               36 (52.2)                              
   High                                 137   91 (66.4)               46 (33.6)                              
  5-year survival                                                                              11.737        0.001[a](#tfn1-ott-11-7459){ref-type="table-fn"}
   No                                   150   101 (67.3)              49 (32.7)                              
   Yes                                  56    23 (41.1)               33 (58.9)                              

**Note:**

*P*\<0.05.

**Abbreviation:** NSCLC, non-small-cell lung cancer.

###### 

Univariate and multivariate analyses of prognostic factors in NSCLC patients for 5-year survival

  Variable                                                                                     Univariate analysis                                  Multivariate analysis                                                        
  -------------------------------------------------------------------------------------------- ---------------------------------------------------- ----------------------- ---------------------------------------------------- ----------------------
  HIPK3 expression                                                                                                                                                                                                               
   Low (n=124) vs high (n=82)                                                                  0.001[a](#tfn3-ott-11-7459){ref-type="table-fn"}     1.883 (1.299--2.729)    \<0.001[a](#tfn3-ott-11-7459){ref-type="table-fn"}   2.007 (1.400--2.877)
  Gender                                                                                                                                                                                                                         
   Male (n=135) vs female (n=71)                                                               0.081                                                0.718 (0.495--1.042)    --                                                   --
  Age (years)                                                                                                                                                                                                                    
   \<60 (n=74) vs ≥60 (n=132)                                                                  0.029[a](#tfn3-ott-11-7459){ref-type="table-fn"}     1.498 (1.042--2.153)    0.006[a](#tfn3-ott-11-7459){ref-type="table-fn"}     1.648 (1.157--2.347)
  Tumor diameter (cm)                                                                                                                                                                                                            
   \<3 (n=139) vs ≥3 (n=67)                                                                    \<0.001[a](#tfn3-ott-11-7459){ref-type="table-fn"}   0.368 (0.238--0.570)    \<0.001[a](#tfn3-ott-11-7459){ref-type="table-fn"}   0.368 (0.246--0.549)
  Smoking status                                                                                                                                                                                                                 
   Never (n=192) vs ever (n=14)                                                                0.430                                                0.752 (0.371--1.526)    --                                                   --
  Pathology grade                                                                                                                                                                                                                
   Well+moderate (n=109) vs poor (n=97)                                                        0.636                                                0.912 (0.624--1.333)    --                                                   --
  Histological type                                                                                                                                                                                                              
   Adenocarcinoma (n=131) vs squamous cell carcinoma (n=66) vs adenosquamous carcinoma (n=9)   0.981                                                1.004 (0.734--1.374)    --                                                   --
  Lymph node metastasis                                                                                                                                                                                                          
   Absent (n=100) vs present (n=106)                                                           0.223                                                1.408 (0.812--2.441)    --                                                   --
  TNM stage                                                                                                                                                                                                                      
   I+II (n=92) vs III+IV (n=114)                                                               \<0.001[a](#tfn3-ott-11-7459){ref-type="table-fn"}   3.149 (1.868--5.309)    \<0.001[a](#tfn3-ott-11-7459){ref-type="table-fn"}   3.600 (2.445--5.300)
  Ki67 expression                                                                                                                                                                                                                
   Low (n=69) vs high (n=137)                                                                  0.027[a](#tfn3-ott-11-7459){ref-type="table-fn"}     0.584 (0.363--0.940)    0.027[a](#tfn3-ott-11-7459){ref-type="table-fn"}     0.641 (0.433--0.950)

**Note:**

*P*\<0.05.

**Abbreviation:** NSCLC, non-small-cell lung cancer.

[^1]: These authors contributed equally to this work
